Natus Medical (Nasdaq: BABY) said last week that its current CEO Jim Hawkins is retiring from their position, with current chief financial officer Jonathan Kennedy slated to take over as prez & chief exec.
Kennedy has operated as CFO since April 2013, while the retiring Hawkins spent 14 years as the chief exec, the Pleasanton, Calif.-based company said.
“It has been a privilege to serve as Natus’ CEO over the past 14 years and I thank Natus’ talented employees for their hard work and partnership on this journey. I am proud of all that we have accomplished in building Natus into the market leader it is today. I have known and worked with Jonathan for several years and am confident that he is the right leader to keep Natus moving forward and delivering market leading products and solutions to our customers and creating value for our shareholders,” Hawkins said in a press release.
“I am honored to lead Natus during this pivotal time in the company’s history. When I joined Natus, I was impressed by the pace at which the company had grown and gained leading positions in its markets. Natus has added neurodiagnostics, neurosurgery and hearing diagnostics to its legacy newborn care business — and with new products like Otoscan, the company has clear potential to meaningfully enhance patient care. I look forward to working with the rest of the Natus leadership team to create value for our shareholders, provide customers and patients with market leading products and services and employees with opportunities to continue to grow as part of a dynamic company,” Kennedy said in prepared remarks.
In addition to the succession plans, Natus said that Kennedy will join the board of directors, and that Dr. Barbara Paul was named board chair. Sharon Villaverde was appointed interim CFO as part of the transition while the company searches for a permanent CFO.
“On behalf of the board of directors, I would like to thank Jim Hawkins for his service and many contributions to Natus. Jim has been a visionary leader who transformed Natus into the strong global company it is today. Jim leaves Natus financially sound with attractive market opportunities and an experienced and stable management team. Jonathan is a proven leader with a deep understanding of our business operations and a clear vision for the future. He has diverse experience leading both technology and medical device companies, spearheading acquisition integration efforts and developing and implementing cost reduction initiatives on a worldwide basis. No one is better prepared than Jonathan to lead Natus into its next phase of growth and value creation and the board has the utmost confidence in him,” Dr. Paul said in a prepared statement.
Hancock Jaffe taps Rankin as CFO
Hancock Jaffe Laboratories (NSDQ:HJLI) said last Friday it tapped Bob Rankin as its new chief financial officer, set to replace Bill Abbott who is retiring on July 20.
Rankin has reviously operated as chief financial officer of gear manufacturer Horsburgh & Scott and a number of other businesses outside medtech.
“Bob Rankin has many years of CFO experience with public companies, and is a welcome addition to our executive management team. We thank Bill Abbott for his years of service to the company and expect a smooth and seamless transition,” CEO Robert Berman said in a press release.
Evident Medical adds Akyuz as medical ventures prez
Evident Medical said today that it hired Erkan Akyuz as its Evident medical ventures prez as the company expands into medical information technology and analytics.
Prior to joining Evident, Akyuz served as exec VP and prez for Change Healthcare’s imaging, workflow and care solutions business. Before that position, Akyuz operated as prez and CEO of Toshiba Medical Systems and Vital Images and exev VP and CTO of Agfa Healthcare.
“We are incredibly pleased to welcome Erkan to the Evident team. He is an accomplished entrepreneur and business leader and widely regarded as a thought leader in new medical technologies and data. Having Erkan join evident is a major milestone as we see the convergence of medical and dental technologies through digitization and analytics. Over the last few years, Erkan has contributed to McKesson/Change Healthcare’s growth in its $3 billion Healthcare IT business. It is rare to find an executive of his caliber in this space,” CEO Paolo Kalaw said in a prepared statement.
“Evident has built a powerful platform that is empowering the historically traditional dental industry to bring their business from traditional to digital. My major contribution here is to accelerate the historically traditional medical industry into operating as next generation practices. The medical industry is a natural extension for Evident as its truly disruptive technology can remove expensive siloed processes that are traditionally used by medical practices and ultimately help consumers,” Akyuz said in a press release.
Myomo said last week it named Micah Mitchell to the newly created role of chief commercial officer.
Prior to joining Myomo, Mitchell held sales management and executive roles at Invacare, Alliance Seating and Mobility and Apria Healthcare group, the company said.
“Now that we have embarked on scaling up our commercial operations to bring the MyoPro to the many people who could benefit from this life-changing product line, we are pleased to have an executive of Micah’s stature join our senior management team. He has a track record of growing revenues, and he will collaborate with our chief marketing officer, chief medical officer and operations management to develop and implement programs that provide the MyoPro to a greater number of patients through our clinical channel partners,” CEO Paul Gudonis said in a press release.
Helius Medical appoints Laux as CCO
Helius Medical Technologies (TSX:HSM) said last week it appointed Jennifer Laux as its new chief commercialization officer, effective July 9.
Laux previously served as VP at Inovio Pharmaceuticals, and has held positions with Boehringer Ingelheim Merck & Co.
“We are delighted to have someone with Jennifer’s exceptional skills and experience in this role. Her experience growing commercial organizations and bringing global products to market will be invaluable as Helius enters its next stage of growth,” Helius’ CEO Philippe Deschamps said in a press release.
“I’m thrilled to join the Helius team, as we prepare to commercialize the company’s innovative PoNSTM technology, for the treatment of chronic balance disorders associated with mild to moderate traumatic brain injury. Helius is positioning itself to serve this large, high unmet needs market and continues to develop its innovative technology with the goal of addressing the symptoms of other neurological diseases or trauma,” Laux said in prepared remarks.